ALK-Abello A/S Series B | Ownership
Companies that own ALK-Abello A/S Series B
ATP Fondsmaeglerselskab A/S
594,466
5.87%
-1,836
1.11%
12/31/2016
Jupiter Asset Management Ltd.
509,788
5.03%
3,226
0.28%
12/31/2016
Norges Bank Investment Management
198,755
1.96%
7,808
0.01%
12/31/2017
The Vanguard Group, Inc.
164,897
1.63%
4,697
0%
07/31/2018
Wellington Management International Ltd.
164,294
1.62%
95,452
0.56%
08/31/2018
BI Asset Management Fondsmæglerselskab A/S
123,053
1.22%
1,300
0.44%
01/31/2018
Nordea Investment Management AB
85,589
0.85%
45,801
0.05%
07/31/2018
M&G Investment Management Ltd.
71,816
0.71%
0
0.02%
03/29/2018
Dimensional Fund Advisors LP
70,795
0.7%
2,937
0%
04/30/2018
BlackRock Fund Advisors
65,048
0.64%
264
0%
09/06/2018
| Address |
Bøge Allé 6-8
Hørsholm CR 2970
Denmark
|
|
Employees
|
- |
| Website |
http://www.alk.net |
| Updated |
07/08/2019 |
| ALK-Abello A/S engages in the production and development of pharmaceutical products to prevent and treat allergies. It also manufactures tablet-based allergy vaccines for pollen, house dust mites, animals, and insect stings. Its treatment comprises allergy vaccines, emergency treatment, and allergy diagnostics. |
